Adriano Gravina - Concepedia

Author

Adriano Gravina

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

Also Known As

A Gravina, A. GRAVINA, A. Gravina, ADRIANO GRAVINA, Adriano Gravina, Aline Peixoto Gravina, Clorinda Schettino, Diego Ripamonti, F Nuzzo, Gravina, Adriano

117

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Azienda Ospedaliera S.Giuseppe Moscati Tumour Institute of Tuscany University of Campania "Luigi Vanvitelli"University of Naples Federico II

About

Adriano Gravina is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	23	975
2	Health Sciences	5	5	167
3	Natural Sciences	1	1	11
4	Biomolecular Engineering	1	1	11
5	Cell Biology	1	1	50

Adriano Gravina

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer Ana Oaknin, Anna V. Tinker, Lucy Gilbert, JAMA Oncology	2020	346
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial Lucia Del Mastro, Sabino De Placido, Paolo Bruzzi, The Lancet Breast OncologyMedicineDose-dense ChemotherapyBreast CancerCancer Treatment	2015	196
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors Thierry André, Dominique Berton, Giuseppe Curigliano, JAMA Network Open	2023	103
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer	2018	86
Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial Emanuela Rossi, Alessandro Morabito, Francesca Di Rella, Journal of Clinical Oncology Tamoxifen ResultHormonal ContraceptiveBreast OncologyHoboe TrialGynecology	2009	80
Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer Rosario Vincenzo Iaffaioli, A. Tortoriello, Gaetano Facchini, Journal of Clinical Oncology	1999	78
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial Francesco Perrone, Michelino De Laurentiis, Sabino De Placido, European Journal of Cancer Ovarian Function SuppressionOncologyBreast OncologyAdjuvant Zoledronic AcidMedicine	2019	68
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Clinical Cancer Research	2023	68
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial Francesco Perrone, Francesco Nuzzo, Francesca Di Rella, Annals of Oncology Breast OncologyEarly Breast CancerMedicineClinical TrialsAdjuvant Chemotherapy	2014	67
Combined regimen of cisplatin, doxorubicin, and ?-2b interferon in the treatment of advanced malignant pleural mesothelioma Héctor Soto Parrà, Lucia Tixi, Fiorenza Latteri, Cancer	2001	51

Page 1